School of Chemistry and Biochemistry, Thapar University, Patiala 147004, India.
Bioorg Med Chem Lett. 2013 Jun 1;23(11):3288-94. doi: 10.1016/j.bmcl.2013.03.107. Epub 2013 Apr 3.
A series of novel regioisomeric hybrids of quinazoline/benzimidazole viz. (3-allyl-2-methyl-3H-benzimidazol-5-yl)-(2-substituted-quinazolin-4-yl)-amine and (1-allyl-2-methyl-1H-benzimidazol-5-yl)-(2-substituted-quinazolin-4-yl)-amine of biological interest were synthesized. All the synthesized compounds were well characterized by (1)H and (13)C NMR as well as mass spectroscopy. The newly synthesized compounds were screened for in vitro antitumor activities against 60 tumor cell lines panel assay. A significant inhibition for cancer cells were observed with compound 9 and also more active against known drug 5-fluorouracil (5-FU) in some tumor cell lines. Compound 9 displayed appreciable anticancer activity against leukemia, colon, melanoma, renal and breast cancer cell lines.
一系列新型的喹唑啉/苯并咪唑区域异构体杂化物,如(3-烯丙基-2-甲基-3H-苯并咪唑-5-基)-(2-取代-喹唑啉-4-基)-胺和(1-烯丙基-2-甲基-1H-苯并咪唑-5-基)-(2-取代-喹唑啉-4-基)-胺,具有生物活性。所有合成的化合物均通过(1)H 和(13)C NMR 以及质谱进行了很好的表征。新合成的化合物在体外对 60 种肿瘤细胞系进行了抗肿瘤活性筛选。化合物 9 对癌细胞具有显著的抑制作用,并且在某些肿瘤细胞系中比已知药物 5-氟尿嘧啶(5-FU)更具活性。化合物 9 对白血病、结肠、黑色素瘤、肾和乳腺癌细胞系表现出明显的抗癌活性。